Article
De novo pulmonary small cell carcinomas and large cell neuroendocrine carcinomas harboring EGFR mutations: Lack of response to EGFR inhibitors.
Lung cancer (Amsterdam, Netherlands) - 1 Apr 2015
Le Xiuning, Desai Neelam V, Majid Adnan, Karp Rebecca S, Huberman Mark S, Rangachari Deepa, Kent Michael S, Gangadharan Sidharta P, Folch Erik, VanderLaan Paul A, Costa Daniel B
Abstract excerpt
INTRODUCTION: Epidermal growth factor receptor (EGFR) mutations are present in 10-20% of all non-small-cell lung cancers and predict for response to EGFR tyrosine kinase inhibitors (TKIs). However, the incidence of these mutations and their ability to predict response to TKIs in high-grade pulmonary neuroendocrine carcinomas [i.e. small cell lung cancer (SCLC) and large cell neuroendocrine carcinoma (LCNEC)] is...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.